Newborn Calf Serum Market, By Origin (New Zealand Origin, U.S. Origin, Australia Origin, and Others (Brazil Origin, Mexico Origin, etc.)), By Application (Drug Discovery, Cell Media Culture, and Others), By End User (Biotechnology & Pharmaceutical Industries, Academic Institutes, and Others (Research labs and Diagnostic Labs, etc.)), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Nov 2022

Code : CMI5331

Pages :420

Formats :

Excel and PDF

Industry : Biotechnology

Regional Analysis

Global Newborn Calf Serum Market – Regional Analysis

On the basis of region, the global newborn calf serum market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa

Among regions, the North America newborn calf serum market is expected to hold a dominant position during the forecast period owing to an increase in vaccine production. For instance, in 2019, Merck & Company Incorporation, a pharmaceutical company increased its overall vaccine supply to 190 million doses worldwide. Apart from this, Merck had expanded its manufacturing capacity for helping Johnson & Johnson produce Covid-19 vaccine. Merck will use its facilities in the U.S. to produce drug substances, formulate, and fill vials of Johnson & Johnson’s vaccine.

The Europe newborn calf serum market was predicted to experience solid growth over the forecast period, owing to increase in collaboration with other market players. For Instance, on 25^th June 2022, BioNTech, a biotechnology company, and Pfizer Inc., a pharmaceutical and biotechnology corporation, collaborated and tested the safety, tolerability, and immunogenicity of one monovalent and one bivalent Omicron-adapted COVID-19 vaccine candidate and reported a positive result. Further, they are planning to discuss these results with scientific and health care authorities, which will enable them to launch Omicron-adapted booster in the market at the earliest.

Support by French government by providing interest free loan to develop independent biotech enterprises, whereby it is expected to drive the growth of newborn calf serum market. For instance, TreeFrog Therapeutics, a biotechnology company, founded in 2018 in France, received US$ 66.7654 M Series B investment in 2021, through which the company has started international expansion in its workforce and facilities for the development and production of cell therapies. The funding will be also used to develop biomimetic C-StemTM technology for clinical-grade production and expand and bring a wide range of cell therapies closer to the clinic.

The Asia Pacific newborn calf serum market is expected to exhibit the fastest growth during the forecast period, owing to increasing investment in life science sector. For instance, on June 28, 2022, Actis, a global investment firm, announced investment over US$ 700 million to develop life science realty asset in India. The investment is planned to build and develop assets under its platform aimed on providing real estate to clients in the life sciences and related sectors in India. Through which it is expected to boost the calf serum market.

Figure 2: Global Newborn Calf Serum Market (US$ Mn), by Region, 2022

North America: U.S. and Canada
Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
Middle East: GCC, Israel, and Rest of Middle East
Africa: South Africa, North Africa, and Central Africa